{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:30:46Z","timestamp":1792218646689,"version":"4.4.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s40265-023-01894-5","type":"journal-article","created":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T05:02:01Z","timestamp":1686114121000},"page":"935-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Glofitamab: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Matt","family":"Shirley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"1894_CR1","unstructured":"Roche Canada. COLUMVI\u00ae (glofitamab for injection) receives Health Canada authorization with conditions for adult patients with relapsed or refractory diffuse large B-cell lymphoma [media release]. 25 Mar 2023. https:\/\/www.rochecanada.com\/en\/media\/roche-canada-news\/COLUMVI-Glofitamab-for-Injection-Receives-Health-Canada-Authorization.html."},{"key":"1894_CR2","unstructured":"Roche Canada. COLUMVI\u00ae product monograph. 2023. https:\/\/www.rochecanada.com\/content\/dam\/rochexx\/roche-ca\/products\/ConsumerInformation\/MonographsandPublicAdvisories\/columvi\/Columvi_PM_E.pdf. Accessed 01 May 2023."},{"key":"1894_CR3","unstructured":"European Medicines Agency. Columvi. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/columvi. Accessed 01 May 2023."},{"key":"1894_CR4","unstructured":"Roche. FDA grants priority review to Roche's bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma [media release]. 06 Jan 2023. http:\/\/www.roche.com."},{"key":"1894_CR5","unstructured":"Chugai Pharmaceutical Co. Conference on FY2022.12 2Q financial results. 21 Jul 2022. https:\/\/www.chugai-pharm.co.jp\/cont_file_dl.php?f=FILE_5_60.pdf&src=%5b%250%5d,%5b%251%5d&rep=137,60. Accessed 01 May 2023."},{"issue":"1","key":"1894_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0241091","volume":"16","author":"F Cremasco","year":"2021","unstructured":"Cremasco F, Menietti E, Speziale D, et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFN\u03b3\/CXCL10-dependent peripheral T cell recruitment in humanized murine model. PLoS ONE. 2021;16(1): e0241091.","journal-title":"PLoS ONE"},{"issue":"3","key":"1894_CR7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","volume":"6","author":"AE Br\u00f6ske","year":"2022","unstructured":"Br\u00f6ske AE, Korfi K, Belousov A, et al. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma. Blood Adv. 2022;6(3):1025\u201337.","journal-title":"Blood Adv"},{"issue":"24","key":"1894_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220\u201331.","journal-title":"N Engl J Med"},{"issue":"18","key":"1894_CR9","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1200\/JCO.20.03175","volume":"39","author":"M Hutchings","year":"2021","unstructured":"Hutchings M, Morschhauser F, Iacoboni G, et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021;39(18):1959\u201370.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"1894_CR10","doi-asserted-by":"publisher","first-page":"12050","DOI":"10.1182\/blood-2022-157544","volume":"140","author":"YQ Song","year":"2022","unstructured":"Song YQ, Zhang HL, Huang HQ, et al. Glofitamab monotherapy demonstrates high complete response rates and manageable safety in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma and \u22652 prior therapies [abstract]. Blood. 2022;140(suppl 1):12050\u20131.","journal-title":"Blood"},{"issue":"suppl 2","key":"1894_CR11","first-page":"54","volume":"45","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Sureda A, Terol MJ, et al. Glofitamab (glofit) in combination with polatuzumab vedotin (pola): preliminary phase Ib\/II data supports the controllable safety and encouraging efficacy in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [title in German, English abstract]. Oncol Res Treat. 2022;45(suppl 2):54.","journal-title":"Oncol Res Treat."},{"issue":"suppl 1","key":"1894_CR12","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood-2022-157732","volume":"140","author":"MS Topp","year":"2022","unstructured":"Topp MS, Tani M, Dickinson M, et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell Lymphoma (DLBCL): results from a phase Ib study [abstract]. Blood. 2022;140(suppl 1):1775\u20137.","journal-title":"Blood"},{"issue":"suppl 1","key":"1894_CR13","doi-asserted-by":"publisher","first-page":"9461","DOI":"10.1182\/blood-2022-157011","volume":"140","author":"M Hutchings","year":"2022","unstructured":"Hutchings M, Carlo-Stella C, Gritti G, et al. CD19 4\u20131BBL (RO7227166) a novel costimulatory bispecific antibody can be safely combined with the T-cell-engaging bispecific antibody glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma [abstract]. Blood. 2022;140(suppl 1):9461\u20133.","journal-title":"Blood"},{"issue":"15_suppl","key":"1894_CR14","doi-asserted-by":"publisher","first-page":"TPS7575","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7575","volume":"39","author":"M Hertzberg","year":"2021","unstructured":"Hertzberg M, Ku M, Catalani O, et al. A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) [abstract no. TPS7575]. J Clin Oncol. 2021;39(15_suppl):TPS7575.","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"1894_CR15","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2021-147636","volume":"138","author":"A Minson","year":"2021","unstructured":"Minson A, Hamad N, Yannakou CK, et al. Trial in progress: a multicentre, parallel arm, open-label trial of frontline R-CHOP\/polatuzumab vedotin-RCHP and glofitamab in younger patients with higher risk diffuse large B cell lymphoma (COALITION) [abstract]. Blood. 2021;138(suppl 1):3571.","journal-title":"Blood"},{"issue":"suppl 1","key":"1894_CR16","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2022-156808","volume":"140","author":"M Dickinson","year":"2022","unstructured":"Dickinson M, Gritti G, Carlo-Stella C, et al. Phase 1 Study of CD19 targeted CD28 costimulatory agonist in combination with glofitamab to enhance T cell effector function in relapsed\/refractory B cell lymphoma [abstract]. Blood. 2022;140(suppl 1):3818\u201320.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01894-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01894-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01894-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T07:14:58Z","timestamp":1744701298000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01894-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1894"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01894-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]},"assertion":[{"value":"7 June 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Matt Shirley is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}